GPT and neutropenia: The most common reported treatment-related adverse events (mostly classified as grade 1 or 2) included increased AST (62.9%) and alanine aminotransferase (ALT) (61.4%), leukopenia (51.4%), hypoesthesia (51.4%) and neutropenia (51.4%).